Literature DB >> 27564643

T Cell Distribution in Relation to HIV/HBV/HCV Coinfections and Intravenous Drug Use.

Eveli Kallas1, Kristi Huik1, Silver Türk1, Merit Pauskar1, Ene-Ly Jõgeda1, Marina Šunina2, Tõnis Karki1, Don Des Jarlais3, Anneli Uusküla4, Radko Avi1, Irja Lutsar1.   

Abstract

Intravenous drug use (IDU) is one of the most important transmission routes for blood borne viruses, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). These infections alter the subset distributions of T cells; however, knowledge of such effects during HIV, HBV, and or HCV coinfection is limited. Therefore, we aimed to evaluate any associations between T cell distribution and the presence of HIV, HBV, and HCV coinfections among persons who inject drugs (PWID). Blood samples from 88 Caucasian PWID (mean age 30; 82% male) and 47 age-matched subjects negative for all three infections (mean age of 29; 83% male) were analyzed. The T cell markers CD3, CD4, CD8, CD45RA, CCR7, HLA-DR, and CCR5 were assessed using flow cytometry. Of the PWID, 40% were HIV+HBV+HCV+, 20% HBV+HCV+, 19% HCV+, and 13% negative for all three infections. The HIV+HBV+HCV+ PWID had lower percentages of CD4+ and higher percentages of CD8+ cells compared to triple negative PWID (p < 0.001 in all cases). The only difference between HBV+HCV+ with triple negative PWID was the lower CD4+ cell percentages among the former (52.1% and 58.6%, p = 0.021). Triple negative PWID had higher immune activation and number of CCR5+ cells compared to the controls. We suggest that the altered T cell subset distribution among PWID is mainly triggered by HIV infection and or IDU, while HBV and or HCV seropositivity has minimal additional effects on CD4+ cell distribution.

Entities:  

Year:  2016        PMID: 27564643      PMCID: PMC5065031          DOI: 10.1089/vim.2016.0057

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  35 in total

1.  Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection.

Authors:  Simona Urbani; Carolina Boni; Barbara Amadei; Paola Fisicaro; Simona Cerioni; Maria Antonietta Valli; Gabriele Missale; Carlo Ferrari
Journal:  Hepatology       Date:  2005-04       Impact factor: 17.425

2.  Chronic immune activation in the T cell compartment of HCV/HIV-1 co-infected patients.

Authors:  Johan K Sandberg; Karolin Falconer; Veronica D Gonzalez
Journal:  Virulence       Date:  2010 May-Jun       Impact factor: 5.882

3.  Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C.

Authors:  Simona Urbani; Carolina Boni; Gabriele Missale; Gianfranco Elia; Cristina Cavallo; Marco Massari; Giovanni Raimondo; Carlo Ferrari
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  Differences in T cell distribution and CCR5 expression in HIV-positive and HIV-exposed seronegative persons who inject drugs.

Authors:  Eveli Kallas; Kristi Huik; Silver Türk; Merit Pauskar; Ene-Ly Jõgeda; Marina Šunina; Tõnis Karki; Don Des Jarlais; Anneli Uusküla; Radko Avi; Irja Lutsar
Journal:  Med Microbiol Immunol       Date:  2015-12-22       Impact factor: 3.402

5.  Surveillance of HIV, hepatitis B virus, and hepatitis C virus in an estonian injection drug-using population: sensitivity and specificity of testing syringes for public health surveillance.

Authors:  Anneli Uuskula; Robert Heimer; Jack Dehovitz; Krista Fischer; Louise-Anne McNutt
Journal:  J Infect Dis       Date:  2005-12-22       Impact factor: 5.226

6.  Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy.

Authors:  J Judy Chang; Fiona Wightman; Angeline Bartholomeusz; Anna Ayres; Stephen J Kent; Joseph Sasadeusz; Sharon R Lewin
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

7.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

8.  Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication.

Authors:  Amber D Steele; Earl E Henderson; Thomas J Rogers
Journal:  Virology       Date:  2003-04-25       Impact factor: 3.616

9.  Association between TLR3 rs3775291 and resistance to HIV among highly exposed Caucasian intravenous drug users.

Authors:  Kristi Huik; Radko Avi; Merit Pauskar; Eveli Kallas; Ene-Ly Jõgeda; Tõnis Karki; Kristina Marsh; Don Des Jarlais; Anneli Uusküla; Irja Lutsar
Journal:  Infect Genet Evol       Date:  2013-08-17       Impact factor: 3.342

Review 10.  Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention.

Authors:  Lucas Wiessing; Marica Ferri; Bart Grady; Maria Kantzanou; Ida Sperle; Katelyn J Cullen; Angelos Hatzakis; Maria Prins; Peter Vickerman; Jeffrey V Lazarus; Vivian D Hope; Catharina Matheï
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

View more
  3 in total

1.  DNA methylation signatures of illicit drug injection and hepatitis C are associated with HIV frailty.

Authors:  Xinyu Zhang; Ying Hu; Amy C Justice; Boyang Li; Zuoheng Wang; Hongyu Zhao; John H Krystal; Ke Xu
Journal:  Nat Commun       Date:  2017-12-21       Impact factor: 14.919

Review 2.  CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention.

Authors:  Yan Yan; Renfang Chen; Xu Wang; Kai Hu; Lihua Huang; Mengji Lu; Qinxue Hu
Journal:  Front Cell Dev Biol       Date:  2019-10-01

3.  Molecular Identification of HIV-1 in the Presence of Hepatitis B Virus and Hepatitis C Virus Co-infections

Authors:  Murat Sayan; Müge Özgüler; Figen Sarıgül Yıldırım; Taner Yıldırmak; Alper Gündüz; Başak Dokuzoğuz; Mustafa Kemal Çelen; Dilara İnan; Yasemin Heper; Gülden Ersöz; İlkay Karaoğlan; Nurgül Ceran; Aydın Deveci; Servet Öztürk; Selda Sayın Kutlu; Hülya Özkan Özdemir; Ayhan Akbulut; Saadet Yazıcı; Alper Şener; Atahan Çağatay; Serhat Ünal
Journal:  Balkan Med J       Date:  2020-02-28       Impact factor: 2.021

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.